A share price of Cytokinetics Inc [CYTK] is currently trading at $46.16, up 10.91%. An important factor to consider is whether the stock is rising or falling in short-term value. The CYTK shares have gain 7.95% over the last week, with a monthly amount drifted -1.51%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cytokinetics Inc [NASDAQ: CYTK] stock has seen the most recent analyst activity on February 07, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $86. Previously, Stifel started tracking the stock with Buy rating on January 22, 2025, and set its price target to $80. On November 08, 2024, RBC Capital Mkts initiated with a Outperform rating and assigned a price target of $80 on the stock. Goldman downgraded its rating to a Neutral and decreased its price target to $60 on August 13, 2024. UBS downgraded its rating to a Neutral and raised its price target to $92 on January 24, 2024. Morgan Stanley downgraded its rating to Equal-Weight for this stock on January 05, 2024, and upped its price target to $90. In a note dated November 09, 2023, Goldman initiated an Buy rating and provided a target price of $50 on this stock.
Cytokinetics Inc experienced fluctuations in its stock price throughout the past year between $40.53 and $81.36. Currently, Wall Street analysts expect the stock to reach $90 within the next 12 months. Cytokinetics Inc [NASDAQ: CYTK] shares were valued at $46.16 at the most recent close of the market. An investor can expect a potential return of 94.97% based on the average CYTK price forecast.
Analyzing the CYTK fundamentals
Trailing Twelve Months sales for Cytokinetics Inc [NASDAQ:CYTK] were 3.22M which represents 22.49% growth. Gross Profit Margin for this corporation currently stands at -28.72% with Operating Profit Margin at -162.98%, Pretax Profit Margin comes in at -179.06%, and Net Profit Margin reading is -179.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is 3.35 and Total Capital is -0.4. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -56.76.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 42.53 points at the first support level, and at 38.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 48.02, and for the 2nd resistance point, it is at 49.89.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cytokinetics Inc [NASDAQ:CYTK] is 9.28. On the other hand, the Quick Ratio is 9.28, and the Cash Ratio is 0.43. Considering the valuation of this stock, the price to sales ratio is 1691.72.
Transactions by insiders
Recent insider trading involved Malik Fady Ibraham, EVP Research & Development, that happened on Feb 04 ’25 when 2000.0 shares were sold. EVP Research & Development, Malik Fady Ibraham completed a deal on Jan 21 ’25 to sell 2000.0 shares. Meanwhile, EVP Research & Development Malik Fady Ibraham sold 2000.0 shares on Jan 07 ’25.
